Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.

Autor: Honeywell RJ; Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Ruiz van Haperen VW; Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands; Advisory Council on Health Research, PO Box 16052, 2500 BB The Hague, The Netherlands., Veerman G; Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands; INC research, Amsterdam, The Netherlands., Smid K; Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands., Peters GJ; Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: gj.peters@vumc.nl.

Publikováno v: The international journal of biochemistry & cell biology [Int J Biochem Cell Biol] 2015 Mar; Vol. 60, pp. 73-81. Date of Electronic Publication: 2015 Jan 03.

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.

Autor: Bergman AM; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands., Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ

Publikováno v: Cancer research [Cancer Res] 2005 Oct 15; Vol. 65 (20), pp. 9510-6.

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.

Autor: Bergman AM; Department of Oncology, University Hospital VU, Amsterdam, The Netherlands., Pinedo HM, Jongsma AP, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, Peters GJ

Publikováno v: Biochemical pharmacology [Biochem Pharmacol] 1999 Feb 15; Vol. 57 (4), pp. 397-406.

Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).

Autor: Ruiz van Haperen VW; Department Clinical Investigation, M. D. Anderson Cancer Center, Houston, Texas, USA., Veerman G, van Moorsel CJ, Peters GJ

Publikováno v: Advances in experimental medicine and biology [Adv Exp Med Biol] 1998; Vol. 431, pp. 637-40.

Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines.

Autor: van Moorsel CJ; Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands., Veerman G, Ruiz van Haperen VW, Bergman AM, Jensen PB, Sehested M, Peters GJ

Publikováno v: Advances in experimental medicine and biology [Adv Exp Med Biol] 1998; Vol. 431, pp. 661-5.